PURPOSE: We determine the maximum tolerated dose (MTD) and efficacy of gemcitabine plus vinorelbine combined with cisplatin in patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Chemo naive patients with stage IIIA to IV non-small cell lung cancer received outpatient administration of gemcitabine 1,000 mg/m2 and vinorelbine 25 mg/m2 intravenously on days 1 and 8 every 21 days. Doses of gemcitabine and vinorelbine were escalated by 250 mg/m2 and 5 mg/m2, respectively, at each dose level. Cisplatin was administered at a fixed dose of 50 mg/m2 on days 2 and 9. After the MTD was reached, the study was continued as a phase II trial. RESULTS: From January 1998 to March 1999, sixty-five patients were enrolled. The first 38 patients participated in the phase I evaluation. After 130 cycles, the dose-limiting toxicities were neutropenia, stomatitis, asthenia, and hepatotoxicity occurring at the third and fourth dose levels (doses of gemcitabine/vinorelbine of 1,500/25 and 1,000/30 mg/m2). For the subsequent phase II evaluation, 27 additional patients, out of a total of 53, receiving the MTD of gemcitabine and vinorelbine (1000-1250/25 mg/m2) followed (24 hours later) by cisplatin 50 mg/m2. Thirty one (58%) of 53 assessable patients responded. Objective response for patients with stages III and IV disease, respectively, were 65% and 47%. The median time to progression and the overall survival time were 9 months (95% CI: 5-12) and 11 months (95% CI: 9-13), respectively. World Health Organization toxicity > or = grade 3 neutropenia was registered in 28 (54%) of 52 assessable patients (2% with febrile neutropenia), and > or = grade 3 thrombocytopenia in 15 (29%) patients (4% with bleeding). Nausea/vomiting (> or = grade 2) and asthenia (moderate to severe) occurred in 24 (46%) and 14 (27%) patients, respectively. CONCLUSION: Gemcitabine 1,000-1,250 mg/m2 plus vinorelbine 25 mg/m2 on days 1 and 8, followed by cisplatin 50 mg/m2 24 hours later, is safe for outpatient administration and active in patients with NSCLC.
PURPOSE: We determine the maximum tolerated dose (MTD) and efficacy of gemcitabine plus vinorelbine combined with cisplatin in patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Chemo naive patients with stage IIIA to IV non-small cell lung cancer received outpatient administration of gemcitabine 1,000 mg/m2 and vinorelbine 25 mg/m2 intravenously on days 1 and 8 every 21 days. Doses of gemcitabine and vinorelbine were escalated by 250 mg/m2 and 5 mg/m2, respectively, at each dose level. Cisplatin was administered at a fixed dose of 50 mg/m2 on days 2 and 9. After the MTD was reached, the study was continued as a phase II trial. RESULTS: From January 1998 to March 1999, sixty-five patients were enrolled. The first 38 patients participated in the phase I evaluation. After 130 cycles, the dose-limiting toxicities were neutropenia, stomatitis, asthenia, and hepatotoxicity occurring at the third and fourth dose levels (doses of gemcitabine/vinorelbine of 1,500/25 and 1,000/30 mg/m2). For the subsequent phase II evaluation, 27 additional patients, out of a total of 53, receiving the MTD of gemcitabine and vinorelbine (1000-1250/25 mg/m2) followed (24 hours later) by cisplatin 50 mg/m2. Thirty one (58%) of 53 assessable patients responded. Objective response for patients with stages III and IV disease, respectively, were 65% and 47%. The median time to progression and the overall survival time were 9 months (95% CI: 5-12) and 11 months (95% CI: 9-13), respectively. World Health Organization toxicity > or = grade 3 neutropenia was registered in 28 (54%) of 52 assessable patients (2% with febrile neutropenia), and > or = grade 3 thrombocytopenia in 15 (29%) patients (4% with bleeding). Nausea/vomiting (> or = grade 2) and asthenia (moderate to severe) occurred in 24 (46%) and 14 (27%) patients, respectively. CONCLUSION:Gemcitabine 1,000-1,250 mg/m2 plus vinorelbine 25 mg/m2 on days 1 and 8, followed by cisplatin 50 mg/m2 24 hours later, is safe for outpatient administration and active in patients with NSCLC.
Authors: F Cardenal; M P López-Cabrerizo; A Antón; V Alberola; B Massuti; A Carrato; I Barneto; M Lomas; M García; P Lianes; J Montalar; C Vadell; J L González-Larriba; B Nguyen; A Artal; R Rosell Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: P Comella; G Frasci; N Panza; L Manzione; V Lorusso; G Di Rienzo; R Cioffi; G De Cataldis; L Maiorino; D Bilancia; G Nicolella; M Natale; F Carpagnano; C Pacilio; M De Lena; A Bianco; G Comella Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544
Authors: G Frasci; N Panza; P Comella; G P Nicolella; M Natale; C Pacilio; A Gravina; V Caputi; G Botti; G Comella Journal: Ann Oncol Date: 1997-10 Impact factor: 32.976
Authors: C Manegold; B Bergman; A Chemaissani; W Dornoff; P Drings; P Kellokumpu-Lehtinen; K Liippo; K Mattson; J van Pawel; S Ricci; C Sederholm; R A Stahel; G Wagenius; N van Walree; W ten Bokkel-Huinink Journal: Ann Oncol Date: 1997-06 Impact factor: 32.976
Authors: U Gatzemeier; F A Shepherd; T Le Chevalier; P Weynants; B Cottier; H J Groen; R Rosso; K Mattson; H Cortes-Funes; M Tonato; R L Burkes; M Gottfried; M Voi Journal: Eur J Cancer Date: 1996-02 Impact factor: 9.162
Authors: D R Gandara; J Crowley; R B Livingston; E A Perez; C W Taylor; G Weiss; J R Neefe; L F Hutchins; R W Roach; S M Grunberg Journal: J Clin Oncol Date: 1993-05 Impact factor: 44.544
Authors: T Le Chevalier; D Brisgand; J Y Douillard; J L Pujol; V Alberola; A Monnier; A Riviere; P Lianes; P Chomy; S Cigolari Journal: J Clin Oncol Date: 1994-02 Impact factor: 44.544
Authors: Emilio Esteban; Joaquin Fra; Yolanda Fernández; Norberto Corral; José M Vieitez; Isabel Palacio; José L de Sande; José L Fernández; Isabel Muñiz; Noemi Villanueva; Enrique Estrada; Beatriz Mareque; Esther Uña; José M Buesa; Angel J Lacave Journal: Invest New Drugs Date: 2006-05 Impact factor: 3.651